What is beyond the Nivolumab Monotherapy approval for advanced Hepatocellular Carcinoma?
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 2
Abstract
With an estimated 500,000 new cases per year, hepatocellular carcinoma (HCC) represents the third leading cause of cancer death worldwide. The incidence is rising in the west, largely due to an increasing incidence of hepatitis C virus infection [1]. The majority of HCC patients are diagnosed with disease too advanced for curative treatment. Only liver resection and liver transplantation are considered curative, with poor efficiency of other modalities such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE), although this may provide a modest prolongation in survival; however, the relapse in the majority of these patients is inevitable [2]. An array of translational research and pilot clinical trials have revealed that adoptive immunotherapy's are safe by patients with HCC, but they lack efficacy [3]. Now, we are in the new era of immunotherapy's such as immune checkpoint inhibitors and CAR-T strategies, which would bring benefit to the HCC patients. On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol- Myers Squibb Co.) for the treatment of HCC in patients who have been previously treated with sorafenib. The approval was based on a 154-patient subgroup of CHECKMATE-040 (NCT 01658878), a multicenter, open-label trial conducted in patients with HCC and Child-Pugh.
Authors and Affiliations
Luis Mendoza
Keywords
Related Articles
- EP ID EP583053
- DOI 10.32474/OAJOM.2018.01.000109
- Views 84
- Downloads 0
Acute Erythroblastic Leukemia Revealed by Dermatological Manifestations
Acute erythroblastic leukemia is characterized by the proliferation of a predominant erythrocyte population on other lineages. Cutaneous manifestations remain rare and misleading, making the diagnosis of difficult to sus...
Pilomatricoma Localized in the Arm: A Rare Case Report
A pilomatricoma is a rare, benign skin tumour originating from the hair follicle cells. It accounts for 0.15 of skin tumours is. It usually involves the head and neck region. The definitive diagnosis is based on histolog...
Traditional Medicine in Contextual African Society: On-Going Challenges
The role of traditional medicine in contextual African society cannot be overemphasized. Due to the less financial implication on the part of patients(s) patronizing the medicine to treat a particular ailment. In recent...
A Case Report and Review of Thymic Carcinoma with Adenoid Cystic Carcinoma like Features
Adenoid cystic carcinoma (ACC) is also called cylindroma, which is considered as a kind of low-grade malignant tumor and often occurs in head and neck salivary gland tissue. Most of them happened in submandibular gland a...
Benign Metastasizing Leiomyoma and Intravenous Leiomyomatosis Following Total Hysterectomy: Two Case Reports and a Literature Review
Uterine leiomyomas are the most common gynecological tumor in women of reproductive age. These tumors are typically benign entities, but uncommonly transition toward tissues of malignant potential. Rare growth patterns o...